Review Reports

Round 1

Reviewer 1 Report

This paper is very interesting. Introduction could be improved a little. Please add in the introduction also place i DM patient, please see doi: 10.1177/1074248420941675

Study is very well designed. Results and discussion are well presented.

Tables /Figures - concise and adequately present results.

Conclusion need to be a little expanded, e.g. add more specifically future ways ii this field.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Lin et al have assessed the use of cilostazol treatment in patients with CAD. This is a very clear and carefully designed study with promising outcome. 

Incidence of CAD/CVD is many fold higher in patients with metabolic disease, especially diabetes. It is unclear in this study if there were any direct correlations were made between diabetic and non-diabetic patients with CVD, for instance, did cilostazol treatment showed better clinical outcome in diabetics ? 

On another note, does cilostazol treatment have more or similar treatment benefits like statins ? Discussing this will help highlight the potential of this drug. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx